ATE214601T1 - Rekombinantes vielwertiges m-protein-vakzin - Google Patents

Rekombinantes vielwertiges m-protein-vakzin

Info

Publication number
ATE214601T1
ATE214601T1 AT93922201T AT93922201T ATE214601T1 AT E214601 T1 ATE214601 T1 AT E214601T1 AT 93922201 T AT93922201 T AT 93922201T AT 93922201 T AT93922201 T AT 93922201T AT E214601 T1 ATE214601 T1 AT E214601T1
Authority
AT
Austria
Prior art keywords
protein vaccine
value
vaccine
recombinant multi
recombinant
Prior art date
Application number
AT93922201T
Other languages
English (en)
Inventor
James B Dale
James W Lederer Jr
Original Assignee
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Corp filed Critical Univ Tennessee Res Corp
Application granted granted Critical
Publication of ATE214601T1 publication Critical patent/ATE214601T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93922201T 1992-09-16 1993-09-15 Rekombinantes vielwertiges m-protein-vakzin ATE214601T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94595492A 1992-09-16 1992-09-16
PCT/US1993/008703 WO1994006421A1 (en) 1992-09-16 1993-09-15 Recombinant multivalent m protein vaccine

Publications (1)

Publication Number Publication Date
ATE214601T1 true ATE214601T1 (de) 2002-04-15

Family

ID=25483752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93922201T ATE214601T1 (de) 1992-09-16 1993-09-15 Rekombinantes vielwertiges m-protein-vakzin

Country Status (10)

Country Link
US (1) US6063386A (de)
EP (1) EP0625043B1 (de)
AT (1) ATE214601T1 (de)
AU (1) AU5128493A (de)
CA (1) CA2123579C (de)
DE (1) DE69331733T2 (de)
DK (1) DK0625043T3 (de)
ES (1) ES2170075T3 (de)
IL (1) IL107025A0 (de)
WO (1) WO1994006421A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
IL107026A0 (en) * 1992-09-16 1993-12-28 Univ Tennessee Res Corp Antigen of hybrid m protein and carrier for group a streptococcal vaccine
DE69331733T2 (de) * 1992-09-16 2002-08-22 The University Of Tennessee Research Corp., Knoxville Rekombinantes vielwertiges m-protein-vakzin
WO1996009395A2 (de) * 1994-09-21 1996-03-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Arzneimittel zur prophylaxe und behandlung von und diagnostika zur erkennung von autoimmunkrankheiten und viralen erkrankungen
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
US6287574B1 (en) * 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6716433B1 (en) 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
EP1801217A1 (de) * 1997-09-12 2007-06-27 The University of Tennessee Research Foundation Streptokokken-Impfstoffgruppe
ATE349527T1 (de) * 1997-09-12 2007-01-15 Univ Tennessee Res Foundation Gruppe a streptokokken-impfstoff
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
AU762100B2 (en) * 1998-12-22 2003-06-19 University Of Tennessee Research Corporation, The Protective antigen of group A Streptococci (SPA)
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
DK1294771T3 (da) * 2000-06-12 2008-12-15 Univ Saskatchewan Kimært GapC-protein fra Streptococcus og anvendelse deraf til vaccinering og diagnosticering
US7160547B2 (en) 2000-10-10 2007-01-09 University Of Tennessee Research Corporation Streptococcal streptolysin S vaccines
WO2002057315A2 (en) * 2000-10-10 2002-07-25 University Of Tennessee Research Corporation Streptococcal streptolysin s vaccines
CA2447017A1 (en) * 2001-05-15 2002-11-21 Shire Biochem Inc. Moraxella(branhamella) catarrhalis antigens
AU2011232787B2 (en) * 2001-05-18 2013-05-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group A streptococci
WO2002094851A2 (en) * 2001-05-18 2002-11-28 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
AU2008203277B2 (en) * 2001-05-18 2011-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group A streptococci
US7270827B2 (en) 2001-10-26 2007-09-18 University Of Tennessee Research Foundation Multivalent streptococcal vaccine compositions and methods for use
US7476390B2 (en) 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US20040151737A1 (en) * 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
WO2005017093A2 (en) * 2003-08-15 2005-02-24 Id Biomedical Corporation Polypeptides of streptococcus pyogenes
EP1864996A1 (de) * 2006-06-06 2007-12-12 Helmholtz-Zentrum für Infektionsforschung GmbH Peptid das mit rheumatischem Fieber verbunden ist und dessen Verwendung als diagnostischer Marker.
US9289485B2 (en) * 2006-11-30 2016-03-22 Luiza Guilherme Guglielmi Therapeutic application of S. pyogenes C-terminal peptide
BRPI0604997A (pt) * 2006-11-30 2007-05-22 Fundacao Zerbini vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção
SI2144924T1 (sl) * 2007-04-16 2016-12-30 Minervax Aps Cepivo s fuzijskimi beljakovinami
EA017887B1 (ru) * 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
MX2011004755A (es) 2008-11-05 2011-10-10 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs).
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
AU2012271336B2 (en) 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
WO2014124446A1 (en) 2013-02-11 2014-08-14 University Of Tennessee Research Foundation Group a streptococcal m-related proteins and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284537A (en) * 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4597967A (en) * 1982-07-27 1986-07-01 The University Of Tennessee Research Corp. Synthetic polypeptide fragments
US4454121A (en) * 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4521334A (en) * 1982-07-27 1985-06-04 The University Of Tennesse Research Corporation Synthetic polypeptide fragments
US4919930A (en) * 1983-06-10 1990-04-24 University Of Tennessee Research Corporation Synthetic M proteins-streptococci type 5
US4784948A (en) * 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
US4705684A (en) * 1985-05-31 1987-11-10 The University Of Tennessee Research Corporation Synthetic M proteins - streptococci type 6
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
WO1993021220A1 (en) * 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
DE69331733T2 (de) * 1992-09-16 2002-08-22 The University Of Tennessee Research Corp., Knoxville Rekombinantes vielwertiges m-protein-vakzin

Also Published As

Publication number Publication date
WO1994006421A1 (en) 1994-03-31
DE69331733D1 (de) 2002-04-25
EP0625043A1 (de) 1994-11-23
AU5128493A (en) 1994-04-12
DE69331733T2 (de) 2002-08-22
CA2123579A1 (en) 1994-03-31
ES2170075T3 (es) 2002-08-01
DK0625043T3 (da) 2002-04-22
EP0625043B1 (de) 2002-03-20
IL107025A0 (en) 1993-12-28
CA2123579C (en) 2005-05-10
EP0625043A4 (en) 1997-05-21
US6063386A (en) 2000-05-16

Similar Documents

Publication Publication Date Title
ATE214601T1 (de) Rekombinantes vielwertiges m-protein-vakzin
DK0618813T3 (da) Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
DE3853454D1 (de) Therapeutische Zusammensetzungen gegen Streptokokken-Infektionen, transformierte Wirte, Verfahren zur Immunisierung und gentechnologisch hergestellte Produkte.
ATE132195T1 (de) Rekombinant-mykobakterielle impfstoffe
ATE359370T1 (de) Heterologe antigene in stämmen zur impfung mit lebendzellen
ATE359084T1 (de) Modifizierter hitzeschockprotein/peptidantigen komplex
MX9207113A (es) Fragmento de adn, peptido que comprende una proteina superficial ha de un virus de gripe a y vacuna que comprende tal peptido.
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
DK263390D0 (da) Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression
ATE301716T1 (de) Vmp-ähnliche sequenzen von pathogener borrelia
CY1105600T1 (el) Κατασκευασματα νουκλεϊκων οξεων για γενετικη ανοσοποιηση
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
NO902251L (no) Fremstilling av gonoreiske p1-proteiner og vaksiner.
DK1274853T3 (da) Materialer og fremgangsmåder, der angår immunreaktioner på fusionsproteiner
WO2002020038A3 (en) Method for down-regulating ige
ATE124420T1 (de) Impfstoffe und testsätze für haemophilus influenzae.
DE69332264D1 (de) Mutanten des infektiösen rinder rhinotracheitis-virus und impfstoffe
EP0193585A4 (de) Kreuzreaktive und schützende epitope von circumsporozoit-proteinen.
DK0691404T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
Uchiyama Intracytoplasmic Localization of Antigenic Heat‐Stable 120‐to 130‐Kilodalton Proteins (PS120) Common to Spotted Fever Group Rickettsiae Demonstrated by Immunoelectron Microscopy
DK1176192T3 (da) Helicobacter felis-vaccine
EP0949333A4 (de) Mutierte antigene des masernvirus und die dafür kodierenden gene.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties